KLI

Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastoma

Metadata Downloads
Abstract
Background Prognostic factors in hepatoblastoma need to be reevaluated considering the advances in treatment modalities. The study aimed to evaluate current outcomes of hepatoblastoma and reappraise the association of prognostic factors, including pre-treatment extent of tumor (PRETEXT) stage with annotation factors and Children's Hepatic tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system, with survival outcomes.

Methods We evaluated 103 consecutive patients with hepatoblastoma retrospectively according to the treatment period based on the introduction of a liver transplantation program.

Results The 5-year overall survival (OS), event-free survival (EFS), and transplant-free survival rates were 80.2%, 74.2%, and 61.8%, respectively. EFS and OS were improved significantly from 58.6% to 81.6% (P = 0.024) and from 58.6% to 90.8% (P < 0.001), respectively, in the late period (N = 74) compared with the early period (N = 29). The PRETEXT stage was significant or marginally significant for EFS and OS in the early period but not in the late period. The P, F, R, and C factors were significant for OS and EFS in the early period. However, in the late period, only the P factor was significant for OS, and the F and M factors were significant for EFS. The CHIC-HS system was significant or marginally significant for EFS in both the early and late periods; however, it was significant for OS only in the early period.

Conclusion Survival rates were significantly improved in children with hepatoblastoma, especially in those with advanced PRETEXT stages with positive annotation factors and in a high-risk CHIC-HS group. Prognostic factors had different clinical implications with evolved treatment modalities.
Author(s)
고경남남궁정만윤희망조영아최세훈신주희강성한서진경김혜리오석희김경모김대연임호준
Issued Date
2021
Type
Article
Keyword
CHIC-HSPRETEXThepatoblastomapediatricprognostic factor
DOI
10.1002/cam4.3897
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7598
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_doaj_primary_oai_doaj_org_article_eaffc05b1d324902ba11b92f5e35edbd&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,Recent%20improvement%20in%20survival%20outcomes%20and%20reappraisal%20of%20prognostic%20factors%20in%20hepatoblastoma&amp;sortby=rank&amp;pcAvailability=true
Publisher
CANCER MEDICINE
Location
영국
Language
영어
ISSN
2045-7634
Citation Volume
10
Citation Number
10
Citation Start Page
3261
Citation End Page
3273
Appears in Collections:
Medicine > Medicine
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.